Standard BioTools (NASDAQ: LAB) plans 15% workforce cut with about $7.5M in restructuring costs

Rhea-AI Filing Summary

Standard BioTools Inc. has begun a restructuring plan that includes reducing its global workforce by approximately 15%. The company explains that this move is intended to improve operational efficiency and lower operating costs so they better match its current revenue projections, while still supporting its long-term strategic plan.

The company expects to record about $7.5 million in expenses related to this reduction-in-force, mainly for cash severance, termination benefits, and related costs. These costs are expected to be paid over the next several months, and the company notes that actual expenses could differ and that additional costs may arise in connection with the broader operational restructuring.

Positive

• None.

Negative

• Workforce reduction and restructuring costs: Standard BioTools is reducing its global workforce by approximately 15% and expects to incur about $7.5 million in severance and related expenses, which could adversely affect sales and development activities.

Insights

Equity analyst – restructurings and operating efficiency

Standard BioTools is cutting 15% of staff and booking about $7.5M in restructuring charges.

Standard BioTools Inc. is implementing a restructuring plan that includes a reduction-in-force of approximately 15% of its total global workforce. The stated goal is to align operating costs with current revenue projections and to support execution of the company’s long-term strategic plan. This indicates management is responding to revenue conditions by resetting its cost base.

The company expects expenses tied to the reduction-in-force to be about $7.5 million, primarily cash severance, termination benefits, and related costs, payable over the next several months. It also notes that these estimates are based on assumptions and that actual results may differ, with potential additional costs associated with the broader operational restructuring. The filing cautions that workforce and expense reductions could adversely affect sales and development activities, underscoring execution risk around maintaining growth while cutting resources.

false000116219400011621942025-09-132025-09-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 13, 2025

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
2 Tower Place, Suite 2000 South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05. Costs Associated with Exit or Disposal Activities

On September 13, 2025, Standard BioTools Inc. (the “Company”) commenced a restructuring plan, including a reduction-in-force of approximately 15% of its total global workforce. The purpose of this restructuring plan, including the reduction-in-force, is to improve operational efficiency and reduce operating costs of its continuing operations in line with the Company’s current revenue projections, while supporting the execution of the Company’s long-term strategic plan.

The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $7.5 million. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the operational restructuring plan, including the reduction-in-force. The Company expects these costs to be payable over the next several months.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs and timing of costs associated with the reduction-in-force, expected reductions of operating expenses, and the Company’s expectations with respect to current revenue projections. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company’s costs may be greater than anticipated and the workforce and operating expense reductions may have an adverse impact on the Company’s sales and development activities. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and its other filings filed from time to time with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statement, except as required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:		September 17, 2025		STANDARD BIOTOOLS INC.
				By:		/s/ Alex Kim
				Name:		Alex Kim
				Title:		Chief Financial Officer

FAQ

What restructuring did Standard BioTools (LAB) announce?

Standard BioTools Inc. commenced a restructuring plan that includes a reduction-in-force of approximately 15% of its total global workforce to improve operational efficiency and reduce operating costs in line with its current revenue projections.

How much will Standard BioTools’ workforce reduction cost?

The company currently expects expenses related to the reduction-in-force to be approximately $7.5 million, consisting primarily of cash severance, termination benefits, and related costs.

Over what period will Standard BioTools pay the restructuring costs?

Standard BioTools expects the costs associated with the reduction-in-force to be payable over the next several months.

Why is Standard BioTools (LAB) cutting about 15% of its workforce?

The company states that the restructuring, including the 15% workforce reduction, is intended to improve operational efficiency, reduce operating costs of its continuing operations in line with current revenue projections, and support execution of its long-term strategic plan.

What risks does Standard BioTools highlight related to the restructuring?

The company notes that actual costs may be greater than anticipated, additional costs may arise from the restructuring, and that workforce and operating expense reductions may have an adverse impact on its sales and development activities.

Does Standard BioTools provide any forward-looking warnings about this restructuring?

Yes. The company describes statements about expected restructuring costs, timing, and operating expense reductions as forward-looking and subject to significant risks and uncertainties, including the risk that costs are higher than expected and that the reductions negatively affect sales and development.